Filters
Results 1 - 10 of 581
Results 1 - 10 of 581.
Search took: 0.021 seconds
Sort by: date | relevance |
AbstractAbstract
[en] Angiotensin II (Ang II), the main effector of the renin angiotensin system, acts upon two distinct transmembrane receptors, the Ang II type 1 and the type 2 (AT_2-) receptor, to induce promotion and inhibition of ERK2 phosphorylation. The AT_2-receptor, through an interaction with its putative signaling partner MTUS1/ATIP (AT_2-receptor interacting protein), inhibits the mitogenic effects of EGF in prostate cancer cell lines representing both early and late stage disease. This is the first report on the expression of ATIP in normal and malignant human prostatic biopsies. The expression of ATIP and its major isoforms, ATIP1 and ATIP3, in normal prostatic cells and three prostate cancer cell lines was examined using QPCR and immunohistochemistry. Human biopsies containing benign prostatic hyperplasia (BPH), high grade prostatic intraepithelial neoplasia (HGPIN) and well, moderately and poorly differentiated prostate cancer were also examined. Overall, ATIP1 and ATIP3 mRNA expression was increased in malignant compared to normal tissues and cell lines. ATIP immunostaining was low or absent in both the basal and columnar epithelial cell layers surrounding BPH acini; however, it was observed in high concentration in neoplastic epithelial cells of HGPIN and was clearly evident in cytoplasms of malignant cells in all prostate cancer grades. ATIP immunostaining was also identified in the cytoplasms of LNCaP and PC3 prostate cancer cells. As the AT_2-receptor/ATIP inhibitory signaling pathway exists in malignant cells in all grades of prostate cancer, enhancement of this pathway may be a therapeutic target even after the development of androgen-independence
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers3043824; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763398; PMCID: PMC3763398; PMID: 24213113; PUBLISHER-ID: cancers-03-03824; OAI: oai:pubmedcentral.nih.gov:3763398; Copyright (c) 2011 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license(http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 3(4); p. 3824-3837

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Bharali, Dhruba J.; Siddiqui, Imtiaz A.; Adhami, Vaqar M.; Chamcheu, Jean Christopher; Aldahmash, Abdullah M.; Mukhtar, Hasan; Mousa, Shaker A., E-mail: shaker.mousa@acphs.edu2011
AbstractAbstract
[en] The advent of nanotechnology has had a revolutionary impact on many aspects of 21"s"t century life. Nanotechnology has provided an opportunity to explore new avenues that conventional technologies have been unable to make an impact on for diagnosis, prevention, and therapy of different diseases, and of cancer in particular. Entities in nanometer sizes are excellent platforms to incorporate various drugs or active materials that can be delivered effectively to the desired action site without compromising the activity of the incorporated drug or material. In particular, nanotechnology entities can be used to deliver conventional natural products that have poor solubility or a short half life. Conventional natural products used with entities in nanometer sizes enable us to solve many of the inherent problems (stability, solubility, toxicity) associated with natural products, and also provide a platform for targeted delivery to tumor sites. We recently introduced the novel concept of using nanotechnology for enhancing the outcome of chemoprevention, which we called ‘nanochemoprevention’. This idea was subsequently exploited by several laboratories worldwide and has now become an advancing field in chemoprevention research. This review examines some of the applications of nanotechnology for cancer prevention and therapy using natural products
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers3044024; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763408; PMCID: PMC3763408; PMID: 24213123; PUBLISHER-ID: cancers-03-04024; OAI: oai:pubmedcentral.nih.gov:3763408; Copyright (c) 2011 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 3(4); p. 4024-4045

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] It is well-established that the actin cytoskeleton plays an important role in tumor development yet the contribution made by nuclear actin is ill-defined. In a recent study, nuclear actin was identified as a key mediator through which laminin type III (LN1) acts to control epithelial cell growth. In the breast, epithelial tumors are surrounded by an environment which lacks LN1. These findings point to actin as a potential mediator of tumor development. Here our current understanding of the roles of cytoplasmic and nuclear actin in normal and tumor cell growth is reviewed, relating these functions to cell phenotype in a tissue context
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers3044269; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763423; PMCID: PMC3763423; PMID: 24213138; PUBLISHER-ID: cancers-03-04269; OAI: oai:pubmedcentral.nih.gov:3763423; Copyright (c) 2011 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 3(4); p. 4269-4280

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Rourke, Elizabeth A.; Lopez, Mirtha S.; Monroy, Claudia M.; Scheurer, Michael E.; Etzel, Carol J.; Albrecht, Thomas; Bondy, Melissa L.; El-Zein, Randa A., E-mail: relzein@mdanderson.org2010
AbstractAbstract
[en] Human cytomegalovirus (HCMV) infection occurs early in life and viral persistence remains through life. An association between HCMV infection and malignant gliomas has been reported, suggesting that HCMV may play a role in glioma pathogenesis and could facilitate an accrual of genotoxic damage in the presence of γ-radiation; an established risk factor for gliomas. We tested the hypothesis that HCMV infection modifies the sensitivity of cells to γ-radiation-induced genetic damage. We used peripheral blood lymphocytes (PBLs) from 110 glioma patients and 100 controls to measure the level of chromosome damage and cell death. We evaluated baseline, HCMV-, γ-radiation and HCMV + γ-radiation induced genetic instability with the comprehensive Cytokinesis-Blocked Micronucleus Cytome (CBMN-CYT). HCMV, similar to radiation, induced a significant increase in aberration frequency among cases and controls. PBLs infected with HCMV prior to challenge with γ-radiation led to a significant increase in aberrations as compared to baseline, γ-radiation and HCMV alone. With regards to apoptosis, glioma cases showed a lower percentage of induction following in vitro exposure to γ-radiation and HCMV infection as compared to controls. This strongly suggests that, HCMV infection enhances the sensitivity of PBLs to γ-radiation-induced genetic damage possibly through an increase in chromosome damage and decrease in apoptosis
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers2020420; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835085; PMCID: PMC3835085; PMID: 24281077; PUBLISHER-ID: cancers-02-00420; OAI: oai:pubmedcentral.nih.gov:3835085; Copyright (c) 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 2(2); p. 420-435

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Tomasetti, Marco; Santarelli, Lory, E-mail: m.tomasetti@univpm.it2010
AbstractAbstract
[en] Malignant mesothelioma (MM) is a rare and aggressive tumour of the serosal cavities linked to asbestos exposure. Improved detection methods for diagnosing this type of neoplastic disease are essential for an early and reliable diagnosis and treatment. Thus, focus has been placed on finding tumour markers for the non-invasive detection of MM. Recently, some blood biomarkers have been described as potential indicators of early and advanced MM cancers. The identification of tumour biomarkers alone or in combination could greatly facilitate the surveillance procedure for cohorts of subjects exposed to asbestos, a common phenomenon in several areas of western countries
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers2020523; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835090; PMCID: PMC3835090; PMID: 24281081; PUBLISHER-ID: cancers-02-00523; OAI: oai:pubmedcentral.nih.gov:3835090; Copyright (c) 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 2(2); p. 523-548

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Shiiba, Masashi; Uzawa, Katsuhiro; Tanzawa, Hideki, E-mail: m.shiiba@faculty.chiba-u.jp2010
AbstractAbstract
[en] MicroRNAs (miRNAs) are small, noncoding RNAs which regulate cell differentiation, proliferation, development, cell cycle, and apoptosis. Expression profiling of miRNAs has been performed and the data show that some miRNAs are upregulated or downregulated in cancer. Several studies suggest that the expression profiles of miRNAs are associated with clinical outcomes. However, the set of miRNAs with altered expressing differs depending on the type of cancer, suggesting that it is important to understand which miRNAs are related to which cancers. Therefore, this review aimed to discuss potentially crucial miRNAs in head and neck squamous cell carcinoma (HNSCC) and oral squamous cell carcinoma (OSCC)
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers2020653; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835097; PMCID: PMC3835097; PMID: 24281087; PUBLISHER-ID: cancers-02-00653; OAI: oai:pubmedcentral.nih.gov:3835097; Copyright (c) 2010 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 2(2); p. 653-669

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Hansen, Torben F.; Spindler, Karen-Lise G.; Andersen, Rikke F.; Lindebjerg, Jan; Kølvraa, Steen; Brandslund, Ivan; Jakobsen, Anders, E-mail: torben.hansen@slb.regionsyddanmark.dk2010
AbstractAbstract
[en] New prognostic markers in patients with colorectal cancer (CRC) are a prerequisite for individualized treatment. Prognostic importance of single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene has been proposed. The objective of the present study was to investigate the prognostic importance of haplotypes in the VEGF-A gene in patients with CRC. The study included 486 patients surgically resected for stage II and III CRC, divided into two independent cohorts. Three SNPs in the VEGF-A gene were analyzed by polymerase chain reaction. Haplotypes were estimated using the PHASE program. The prognostic influence was evaluated using Kaplan-Meir plots and log rank tests. Cox regression method was used to analyze the independent prognostic importance of different markers. All three SNPs were significantly related to survival. A haplotype combination, responsible for this effect, was present in approximately 30% of the patients and demonstrated a significant relationship with poor survival, and it remained an independent prognostic marker after multivariate analysis, hazard ratio 2.46 (95% confidence interval 1.49–4.06), p < 0.001. Validation was provided by consistent findings in a second and independent cohort. Haplotype combinations call for further investigation
Primary Subject
Secondary Subject
Source
Available from http://dx.doi.org/10.3390/cancers2031405; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837313; PMCID: PMC3837313; PMID: 24281164; PUBLISHER-ID: cancers-02-01405; OAI: oai:pubmedcentral.nih.gov:3837313; Copyright (c) 2010 by the authors; licensee MDPI, Basel, Switzerland.; This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 2(3); p. 1405-1418

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Ehehalt, Florian; Franke, Ellen; Pilarsky, Christian; Grützmann, Robert, E-mail: florian.ehehalt@uniklinikum-dresden.de2010
AbstractAbstract
[en] Pancreatic neuroendocrine tumors (PNETs) are rare primary neoplasms of the pancreas and arise sporadically or in the context of genetically determined syndromes. Depending on hormone production and sensing, PNETs clinically manifest due to a hormone-related syndrome (functional PNET) or by symptoms related to tumor bulk effects (non-functional PNET). So far, radical surgical excision is the only therapy to cure the disease. Development of tailored non-surgical approaches has been impeded by the lack of experimental laboratory models and there is, therefore, a limited understanding of the complex cellular and molecular biology of this heterogeneous group of neoplasm. This review aims to summarize current knowledge of tumorigenesis of familial and sporadic PNETs on a cellular and molecular level. Open questions in the field of PNET research are discussed with specific emphasis on the relevance of disease management
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers2041901; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840460; PMCID: PMC3840460; PMID: 24281208; PUBLISHER-ID: cancers-02-01901; OAI: oai:pubmedcentral.nih.gov:3840460; Copyright (c) 2010 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 2(4); p. 1901-1910

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] Genome- and transcriptome-wide data has significantly increased the amount of available information about primary 1,25-dihydroxyvitamin D_3 (1,25(OH)_2D_3) target genes in cancer cell models, such as human THP-1 myelomonocytic leukemia cells. In this study, we investigated the genes G0S2, CDKN1A and MYC as master examples of primary vitamin D receptor (VDR) targets being involved in the control of cellular proliferation. The chromosomal domains of G0S2 and CDKN1A are 140–170 kb in size and contain one and three VDR binding sites, respectively. This is rather compact compared to the MYC locus that is 15 times larger and accommodates four VDR binding sites. All eight VDR binding sites were studied by chromatin immunoprecipitation in THP-1 cells. Interestingly, the site closest to the transcription start site of the down-regulated MYC gene showed 1,25(OH)_2D_3-dependent reduction of VDR binding and is not associated with open chromatin. Four of the other seven VDR binding regions contain a typical DR3-type VDR binding sequence, three of which are also occupied with VDR in macrophage-like cells. In conclusion, the three examples suggest that each VDR target gene has an individual regulatory scenario. However, some general components of these scenarios may be useful for the development of new therapy regimens
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers5041221; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875937; PMCID: PMC3875937; PMID: 24202443; PUBLISHER-ID: cancers-05-01221; OAI: oai:pubmedcentral.nih.gov:3875937; Copyright (c) 2013 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 5(4); p. 1221-1241

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Bikle, Daniel D.; Jiang, Yan, E-mail: daniel.bikle@ucsf.edu2013
AbstractAbstract
[en] Although the epidemiologic evidence that adequate vitamin D nutrition protects against non-melanoma skin cancer (NMSC) is limited, recent evidence that the vitamin D receptor (VDR) is protective is compelling. The role of vitamin D signaling in limiting the proliferation while promoting the differentiation of keratinocytes, the major cell in the epidermis from which NMSC are derived, is well known. However, recent findings that mice lacking the VDR are predisposed to skin cancer has brought to the fore the question of how the VDR is protective. In this review we will look first at the role of vitamin D signaling in regulating the proliferation and differentiation of keratinocytes. We will examine two pathways, β-catenin (CTNNB) and hedgehog (HH), that are regulated by vitamin D signaling and may contribute to the dysregulated proliferation and differentiation in the absence of VDR. We will then examine the failure of VDR deficient keratinocytes to repair DNA damaged by UVB. Finally we will examine the change in long non-coding RNA (LncRNA) expression in VDR null keratinocytes that in other cells is associated with malignant transformation, a potential newly appreciated mechanism by which vitamin D signaling is protective against NMSC
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers5041426; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875946; PMCID: PMC3875946; PMID: 24202452; PUBLISHER-ID: cancers-05-01426; OAI: oai:pubmedcentral.nih.gov:3875946; Copyright (c) 2013 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 5(4); p. 1426-1438

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
1 | 2 | 3 | Next |